Scaling Omics Approaches to Population Size

See talks from the Scaling Omics Approaches to Population Size biobank symposium 11-12 Nov. 2020

Human biological material combined with clinical and demographic registries are the most critical resources for translating the researchbased advances in molecular biology and advanced technologies into improved human health.

Human diversity as dictated by variation in the sequences of genomes can now be characterized in depth at the population scale. Coupled with longitudinal information about disease risk factors, causal processes and outcomes, an unparalleled opportunity currently exists to optimize prevention, diagnosis and treatment of many acute and chronic diseases.

Based on these prerequisites and world-class research communities, several Nordic biobanks have taken giant steps from merely being biorepositories to becoming excellent research communities for genetic epidemiology and translational medicine.

With this biobank symposium, we will bring together world-leading biobanks, researchers and experts in ethical, legal and societal implications to discuss how we can leverage the full potential of omics and achieve population-scale sample sizes. The technical side is important but so is the donor and political perspective.

The symposium is kindly sponsored by the Novo Nordisk Foundation.

Talks will also be made available as audio podcasts at PodBean.

Programme: Scaling Omics Approaches To Population Size (PDF)

Scaling omics1

Proteomics on a population-based scale

Matthias Mann
Max Planck Institute of Biochemistry and Novo Nordisk Foundation
Center for Protein Research

Scaling omics2

Genetics of metabolism in a population isolate - lessons from Greenland

Torben Hansen, Novo Nordisk Foundation Center for Basic Metabolic Research

Scaling omics3

The 500,000 sequencing initiative in the UK Biobank

Naomi Allen, Oxford University and UK Biobank

Scaling omics4

The FinnGen approach to understanding human disease

Mark Daly, Institute for Molecular Medicine Finland and Harvard Medical School

Scaling omics5

Genome-wide association study across pediatric central nervous system tumors implicates shared predisposition and points to 1q25.2 (PAPPA2) and 11p12 (LRRC4C) as novel candidate susceptibility loci.

Jon Foss-Skiftesvik, Rigshospitalet and Statens Serum Institut

Scaling omics6

Scaling Neonatal Metabolomics to Population Size.

Madeleine Ernst, Statens Serum Institut

Scaling omics7

Single-cell analysis of liver biopsies from obese patients – a new approach to understanding fatty liver disease.

Rikard G. Fred, Novo Nordisk Foundation Center for Basic Metabolic Research

Scaling omics8

Leveraging the potential of the Danish National Biobank

Lasse Boding, Danish National Biobank, Statens Serum Institut

Scaling omics9

Biobanking and precision medicine

Kristian Hveem, Norwegian University of Science and Technology

Scaling omics10

The Danish Biobanks and registers as perfect tools for research and precision medicine

Henrik Ullum, Copenhagen University Hospital

Scaling omics11

The Spanish perspective on cancer research

Eva Ortega Paino, Spanish National Cancer Research Centre (CNIO)

Scaling omics12

The Danish contribution to psychiatry through massive unbiased sample collections

Michael Christiansen, Statens Serum Institute and University of Copenhagen

Scaling omics13

Molecular prediction of inflammatory bowel disease

Tine Jess, Statens Serum Institut

Scaling omics14

Gut microbiome and its metabolic functions reflect healthy and unhealthy distribution profiles of lipoproteins.

Josue Castro, University of Copenhagen

Scaling omics15

Clinical potential of adoptive cell therapy with tumor infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients

Anders H. Kverneland, National Center for Cancer Immune Therapy

Scaling omics16

Program for Translational Hematology – Creating a platform for blood cancer research.

Katja Kaastrup, Rigshospitalet and University of Copenhagen

Scaling omics17

Does biobanking have room for ELSI debate anymore?

Aaro Tupasela, University of Helsinki

Scaling omics18

History of Biobanks

Peter Nilsson, Lund University

Scaling omics19

The future for donor consent

Klaus Høyer, University of Copenhagen

Scaling omics20

The political landscape, experiences from the first researcher in the Danish parliament

Stinus Lindgreen, Scientist and Politician. Member of Folketinget

Danish National Biobank

Contact

Danish National Biobank
T. +45 3268 9163 @. mail@nationalbiobank.dk View profile